RADNOR, Pa., Feb. 25, 2016 /PRNewswire/ -- VWR Corporation (NASDAQ: VWR), a leading global, independent provider of products, services and solutions to laboratory and production facilities, today reported its financial results for the fourth quarter and full year ended December 31, 2015.
Highlights:
- 4Q15 record quarterly net sales of $1.11 billion, up 1.0% year-over-year, and up 5.6% on an organic basis.
- 4Q15 Americas and EMEA-APAC segments’ organic net sales increased 6.4% and 4.5%, respectively.
- 4Q15 record quarterly Adjusted EPS of $0.47, up 11.9% compared to $0.42 in the prior year. GAAP EPS was $0.41 in 4Q15 compared to $0.38 in 4Q14.
- 2015 cash flow from operating activities of $225.0 million, up 17.7% vs. $191.1 million in 2014.
- Acquired Therapak, a supplier of pre-packaged convenience kits and procedure packs for clinical trials, pharmaceutical, diagnostic and clinical laboratories on January 4, 2016.
- 2016 guidance: 2016 net sales up 4% to 6% (range of $4.49 to $4.57 billion) and Adjusted EPS up 7% to 12% (range of $1.62 to $1.70).
Manuel Brocke-Benz, President and Chief Executive Officer of VWR, commented: “We are pleased to end fiscal 2015 with strong financial performance, and are encouraged to see that our solid business momentum has continued into the current year. Our record fourth quarter results highlight the multiple factors that VWR is utilizing to drive double-digit Adjusted Earnings Per Share growth. Even with a 6.1% currency headwind and a tough comparison to last year’s 5.9% fourth quarter organic net sales growth, VWR posted positive reported net sales growth in the fourth quarter of 2015. This performance was the direct result of our ongoing passion to find ways to help our customers to win, to take away their pain points and to look for innovative solutions and services to enable them to succeed.”
Mr. Brocke-Benz continued: “Below the operating income line, our ongoing deleveraging initiatives reduced interest expense which along with a lower than expected tax rate, translated our mid-single-digit organic net sales growth and modest margin expansion into an 11.9% year-over-year increase in fourth quarter Adjusted Earnings Per Share. We finished 2015 with a strengthened balance sheet and a motivated employee base, setting the table for continued success as we move through 2016.”
Fourth Quarter 2015 Consolidated Results
Net sales were $1.11 billion, up $10.9 million, or 1.0% compared to prior year. The foreign exchange impact of the strengthening of the U.S. dollar compared to the euro and other major currencies reduced net sales by $67.2 million, or 6.1%. On an organic basis, net sales increased $61.3 million, or 5.6%, while recent acquisitions increased net sales by an additional $16.8 million, or 1.5%.
Operating income was $87.7 million, up $1.4 million, or 1.6% compared to prior year. Excluding the impact of currency, operating income increased by $8.6 million, or 10.0%. The fourth quarter of 2015 included a $0.5 million non-cash earn-out benefit and secondary offering expenses of $0.6 million. Adjusted EPS increased 11.9% year-over-year to $0.47, up from $0.42 in the prior year.
Fourth Quarter 2015 Segment Results
Americas
Net sales were $652.3 million, up $40.9 million, or 6.7% compared to prior year. On an organic basis, net sales increased 6.4% year-over-year. The increase in the Americas net sales was driven by strong sales to biopharma customers.
Operating income was $38.4 million, down $0.4 million, or 1.0% compared to prior year. Fourth quarter 2015 operating income included a $0.5 million non-cash earn-out benefit and secondary offering expenses of $0.6 million.
EMEA-APAC
Net sales were $460.2 million, down $30.0 million, or 6.1% year-over-year. The strengthening of the U.S. dollar as compared to the euro and other currencies reduced net sales by $56.5 million, or 11.5%, while acquisitions added $4.3 million, or 0.9%. On an organic basis, net sales increased 4.5%.
Operating income was $49.3 million, up $1.8 million, or 3.8% compared to prior year. Excluding the impact of currency, operating income increased 18.3% year-over-year.
Full Year 2015 Consolidated Results
Net sales were $4,318.8 million, down $56.5 million compared to prior year, as currency reduced reported net sales by $334.5 million, or 7.6%, while acquisitions added $85.3 million, or 1.9%. Excluding acquisitions and currency, net sales increased $192.7 million, or 4.4%.
Operating income was $320.2 million, up $2.3 million, or 0.7% compared to prior year. Currency reduced operating income by $26.6 million, or 8.4%. In 2015, VWR expanded operating income margin by 10 basis points. The margin expansion was driven by robust organic net sales growth, offset in part by the steep strengthening of the U.S.dollar against the euro and other currencies, which limited our ability to adjust pricing quickly enough to offset the impact of purchasing U.S. denominated products sold into Europe, a change in the Merck supply agreement impacting first quarter 2015 results, and a supply chain disruption involving a single supplier in EMEA-APAC.
Net interest expense declined from $166.3 million in 2014 to $102.8 million in 2015. The lower net interest expense and increase in operating income contributed to a 26.7% increase in Adjusted EPS to $1.52 in 2015.
Greg Cowan, Senior Vice President and Chief Financial Officer commented: “VWR finished the year with net interest expense of $102.8 million, down from $166.3 million in 2014, with the $63.5 million reduction driven by our deleveraging and refinancing initiatives. 2015 was a year of record cash flow for VWR, providing capacity to continue to strengthen our balance sheet and to execute on our value creating acquisition strategy.”
Full Year 2016 Outlook
Management projects 2016 net sales to increase 4% to 6% (range of $4.49 to $4.57 billion) and 2016 Adjusted EPS to increase 7% to 12% (range of $1.62 to $1.70).
Our full year 2016 outlook assumes:
- Currency exchange rates for the remainder of 2016 remain consistent with current rates.
- Interest expense of about $88 million.
- Adjusted diluted shares outstanding of approximately 132 million.
- The income tax rate to calculate full-year 2016 Adjusted EPS of 35%.
- Share-based compensation expense of approximately $10 million before tax.
- No impact from acquisitions closed after February 25, 2016.
Balance Sheet & Cash Flows
At December 31, 2015, total debt was $1.99 billion, down $111 million compared to total debt of $2.10 billion as of December 31, 2014, with the reduction driven by changes in foreign exchange rates and cash flow from operations.
2015 cash generated by operating activities was $225.0 million compared to $191.1 million in 2014. The year-over-year increase was driven by lower cash interest and improved operating results. Capital expenditures in 2015 were $40.9 million compared to $33.6 million in 2014.
Conference Call
As previously announced, VWR Corporation will hold a conference call today, February 25, 2016, to discuss its fourth quarter and full year 2015 financial results beginning at 8:30 a.m. ET. The conference call can be accessed live over the phone by dialing (877) 845-1003, or for international callers, (760) 298-5093. Callers will need to request to join the VWR Corporation fourth quarter 2015 earnings conference call. A replay will be available two hours after the conclusion of the live call and can be accessed by dialing (855) 859-2056, or for international callers, (404) 537-3406. The conference ID number for both the live call and replay will be 34076337. The replay will be available through March 1, 2016. A presentation relating to the conference call will be available at http://investors.vwr.com.
Interested investors and other parties may also listen to a simultaneous webcast of the conference call by logging onto the Investor Relations section of our website at http://investors.vwr.com. The online replay will remain available for a limited time beginning immediately following the call. To learn more about VWR, please visit our website at www.vwr.com.
Use of Non-GAAP Financial Measures
As appropriate, we supplement our results of operations determined in accordance with U.S. generally accepted accounting principles (“GAAP”) with certain non-GAAP financial measurements that we believe are useful to investors, creditors and others in assessing our performance. These measurements should not be considered in isolation or as a substitute for reported GAAP results because they may include or exclude certain items as compared to similar GAAP-based measurements, and such measurements may not be comparable to similarly-titled measurements reported by other companies. Rather, these measurements should be considered as an additional way of viewing aspects of our operations that provide a more complete understanding of our business. We strongly encourage readers to review our consolidated financial statements in their entirety and not rely solely on any one, single financial measurement.
The non-GAAP measurements used in this press release are Adjusted EPS and organic net sales:
- Adjusted EPS is our net income, adjusted for certain items, divided by a normalized number of shares outstanding, reflecting for all periods (i) the total number of shares of common stock outstanding following our initial public offering and the exercise of the underwriters’ option to purchase additional shares, as well as (ii) the dilutive effect, if any, of the assumed exercise or conversion of instruments into common stock as determined under GAAP. For the purposes of calculating adjusted net income, our net income or loss is first adjusted for the following items: (i) amortization of acquired intangible assets, (ii) net foreign currency remeasurement gains or losses relating to financing activities, (iii) impairment charges, (iv) losses on extinguishment of debt, (v) equity offering costs, (vi) income from changes to estimated fair value of contingent consideration and (vii) other costs or credits that are either isolated or cannot be expected to recur with any regularity or predictability. After those adjustments, we then add or subtract an assumed incremental income tax impact on the above noted pre-tax adjustments, using estimated tax rates and any other tax items that are either isolated or cannot be expected to recur with any regularity or predictability.
- Organic net sales is our reported net sales compared to a prior period, reduced by the impact of changes in foreign currency rates and the contribution of acquisitions to the extent not present in prior reported.
Reconciliations of these measurements to the most directly comparable GAAP-based financial measurements are included at the end of this press release.
About VWR Corporation
VWR (NASDAQ: VWR), headquartered in Radnor, Pennsylvania, is a leading, global, independent provider of products, services and solutions to laboratory and production facilities. With sales in excess of $4.3 billion in 2015, VWR enables science for customers in the pharmaceutical, biotechnology, industrial, education, government and healthcare industries. With more than 160 years of experience, VWR has cultivated a value proposition delivering product choice, operational excellence and differentiated services to improve our customers’ productivity from research to production. VWR’s differentiated services provide innovative, flexible and customized solutions from scientific research services to custom-manufactured chemical blends. Our dedicated team of approximately 9,300 associates is focused on supporting scientists, medical professionals and production engineers to achieve their goals.
Forward-Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical fact included in this press release are forward-looking statements. Forward-looking statements discuss our current expectations and projections relating to our financial condition, results of operations, plans, objectives, future performance and business. These statements may be preceded by, followed by or include the words “aim,” “anticipate,” believe,” “estimate,” “expect,” “forecast,” “intend,” “likely,” “outlook,” “plan,” “potential,” “project,” “projection,” “seek,” “can,” “could,” “may,” “should,” “would,” “will,” the negatives thereof and other words and terms of similar meaning.
Forward-looking statements are inherently subject to risks, uncertainties and assumptions; they are not guarantees of performance. You should not place undue reliance on these statements. We have based these forward-looking statements on our current expectations and projections about future events. Although we believe that our assumptions made in connection with the forward-looking statements are reasonable, we cannot assure you that the assumptions and expectations will prove to be correct. Factors that could contribute to these risks, uncertainties and assumptions include, but are not limited to, the factors described in “Risk Factors” in our most recently filed Annual Report on Form 10-K.
All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the foregoing cautionary statements. In addition, all forward-looking statements speak only as of the date of this press release.
To read full press release, please click here.
